Characteristic | IVIG therapy | TPO-RA |
---|---|---|
Time of the beginning of the increase | 3–4 days | 5–7 days |
Time before reaching the maximum | 7 days | 12–16 days |
Effective rate | 70–90% | 80% |
Validity | 2–4 weeks | 2 weeks |
Rate of platelet transfusion avoidance | (−) | 72% |
Adverse events | Headache, fever, nausea | Cytopenia |
Muscle pain, general malaise | Arterial and venous thrombosis | |
Aseptic meningitis | Bone marrow reticulin fibrosis | |
Acute renal failure | Rebound thrombocytopenia after discontinuation (platelet decrease relative to baseline) | |
Infection (HCV, HIV, etc.) | Increases of ALT concentration | |
Thrombosis | Headache | |
Cerebral infarction | ||
Pulmonary infarction | ||
Cost | Venoglobulin IH® 5% IV | REVOLADE® Tablets 12.5 mg 22.61 USD/tablet |
5 g/100 mL = 349.62 USD/vial | REVOLADE® Tablets 25 mg 44.55 USD/tablet | |
In case, 400 mg/kg/day, 50 kg | In our case, preoperative for 23 days, 25 mg/day | |
349.62 × 4 vial × 5 days | + postoperative 30 days | |
= 6992.35 USD | = 2396.96 USD |